Hodgkin Lymphoma, version 2.2015

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Philip Jay Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Nadia Khan, David G. Maloney, Peter M. MauchMonika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, Hema Sundar

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

Original languageEnglish (US)
Pages (from-to)554-586
Number of pages33
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Hodgkin Disease
Therapeutics
Lymphatic System
Combined Modality Therapy
Lymph Nodes
Drug Therapy
Antibodies
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., ... Sundar, H. (2015). Hodgkin Lymphoma, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network, 13(5), 554-586. https://doi.org/10.6004/jnccn.2015.0075

Hodgkin Lymphoma, version 2.2015. / Hoppe, Richard T.; Advani, Ranjana H.; Ai, Weiyun Z.; Ambinder, Richard F.; Aoun, Patricia; Bello, Celeste M.; Benitez, Cecil M.; Bierman, Philip Jay; Blum, Kristie A.; Chen, Robert; Dabaja, Bouthaina; Forero, Andres; Gordon, Leo I.; Hernandez-Ilizaliturri, Francisco J.; Hochberg, Ephraim P.; Huang, Jiayi; Johnston, Patrick B.; Khan, Nadia; Maloney, David G.; Mauch, Peter M.; Metzger, Monika; Moore, Joseph O.; Morgan, David; Moskowitz, Craig H.; Mulroney, Carolyn; Poppe, Matthew; Rabinovitch, Rachel; Seropian, Stuart; Tsien, Christina; Winter, Jane N.; Yahalom, Joachim; Burns, Jennifer L.; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 5, 01.05.2015, p. 554-586.

Research output: Contribution to journalArticle

Hoppe, RT, Advani, RH, Ai, WZ, Ambinder, RF, Aoun, P, Bello, CM, Benitez, CM, Bierman, PJ, Blum, KA, Chen, R, Dabaja, B, Forero, A, Gordon, LI, Hernandez-Ilizaliturri, FJ, Hochberg, EP, Huang, J, Johnston, PB, Khan, N, Maloney, DG, Mauch, PM, Metzger, M, Moore, JO, Morgan, D, Moskowitz, CH, Mulroney, C, Poppe, M, Rabinovitch, R, Seropian, S, Tsien, C, Winter, JN, Yahalom, J, Burns, JL & Sundar, H 2015, 'Hodgkin Lymphoma, version 2.2015', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 5, pp. 554-586. https://doi.org/10.6004/jnccn.2015.0075
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM et al. Hodgkin Lymphoma, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network. 2015 May 1;13(5):554-586. https://doi.org/10.6004/jnccn.2015.0075
Hoppe, Richard T. ; Advani, Ranjana H. ; Ai, Weiyun Z. ; Ambinder, Richard F. ; Aoun, Patricia ; Bello, Celeste M. ; Benitez, Cecil M. ; Bierman, Philip Jay ; Blum, Kristie A. ; Chen, Robert ; Dabaja, Bouthaina ; Forero, Andres ; Gordon, Leo I. ; Hernandez-Ilizaliturri, Francisco J. ; Hochberg, Ephraim P. ; Huang, Jiayi ; Johnston, Patrick B. ; Khan, Nadia ; Maloney, David G. ; Mauch, Peter M. ; Metzger, Monika ; Moore, Joseph O. ; Morgan, David ; Moskowitz, Craig H. ; Mulroney, Carolyn ; Poppe, Matthew ; Rabinovitch, Rachel ; Seropian, Stuart ; Tsien, Christina ; Winter, Jane N. ; Yahalom, Joachim ; Burns, Jennifer L. ; Sundar, Hema. / Hodgkin Lymphoma, version 2.2015. In: JNCCN Journal of the National Comprehensive Cancer Network. 2015 ; Vol. 13, No. 5. pp. 554-586.
@article{765f67a5ac3540ea8125946ed957debb,
title = "Hodgkin Lymphoma, version 2.2015",
abstract = "Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.",
author = "Hoppe, {Richard T.} and Advani, {Ranjana H.} and Ai, {Weiyun Z.} and Ambinder, {Richard F.} and Patricia Aoun and Bello, {Celeste M.} and Benitez, {Cecil M.} and Bierman, {Philip Jay} and Blum, {Kristie A.} and Robert Chen and Bouthaina Dabaja and Andres Forero and Gordon, {Leo I.} and Hernandez-Ilizaliturri, {Francisco J.} and Hochberg, {Ephraim P.} and Jiayi Huang and Johnston, {Patrick B.} and Nadia Khan and Maloney, {David G.} and Mauch, {Peter M.} and Monika Metzger and Moore, {Joseph O.} and David Morgan and Moskowitz, {Craig H.} and Carolyn Mulroney and Matthew Poppe and Rachel Rabinovitch and Stuart Seropian and Christina Tsien and Winter, {Jane N.} and Joachim Yahalom and Burns, {Jennifer L.} and Hema Sundar",
year = "2015",
month = "5",
day = "1",
doi = "10.6004/jnccn.2015.0075",
language = "English (US)",
volume = "13",
pages = "554--586",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Hodgkin Lymphoma, version 2.2015

AU - Hoppe, Richard T.

AU - Advani, Ranjana H.

AU - Ai, Weiyun Z.

AU - Ambinder, Richard F.

AU - Aoun, Patricia

AU - Bello, Celeste M.

AU - Benitez, Cecil M.

AU - Bierman, Philip Jay

AU - Blum, Kristie A.

AU - Chen, Robert

AU - Dabaja, Bouthaina

AU - Forero, Andres

AU - Gordon, Leo I.

AU - Hernandez-Ilizaliturri, Francisco J.

AU - Hochberg, Ephraim P.

AU - Huang, Jiayi

AU - Johnston, Patrick B.

AU - Khan, Nadia

AU - Maloney, David G.

AU - Mauch, Peter M.

AU - Metzger, Monika

AU - Moore, Joseph O.

AU - Morgan, David

AU - Moskowitz, Craig H.

AU - Mulroney, Carolyn

AU - Poppe, Matthew

AU - Rabinovitch, Rachel

AU - Seropian, Stuart

AU - Tsien, Christina

AU - Winter, Jane N.

AU - Yahalom, Joachim

AU - Burns, Jennifer L.

AU - Sundar, Hema

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

AB - Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

UR - http://www.scopus.com/inward/record.url?scp=84995810844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995810844&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0075

DO - 10.6004/jnccn.2015.0075

M3 - Article

C2 - 25964641

AN - SCOPUS:84995810844

VL - 13

SP - 554

EP - 586

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -